Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors

NCT00074321 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

84

Enrollment

NIH

Sponsor class

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: irinotecan hydrochloride
DRUG: oxaliplatin
DRUG: capecitabine
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)